European Lab Evaluation Program to Test Fetal Mutation Assay

Feb 16, 2007

NEW YORK (GenomeWeb News) — EuroGentest is expected to announce next week that it is evaluating a pyrophosphorolysis activated polymerization assay for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.

The PAP assay, a non-invasive prenatal screening test, uses maternal plasma to detect rare mutations and to determine fetal sex.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not a Unique Challenge Anymore

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

The Very Old, Very Young, and Very Talented

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

This Week in PLOS

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Main menu